Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer  

作　　者：Fuyuhiko Motoi 

机构地区：[1]Department of Surgery I,Yamagata University,Yamagata 990-9585,Japan

出　　处：《Cancer Drug Resistance》2021年第4期881-884,共4页癌症耐药（英文）

基　　金：This work was supported in part by JSPS KAKENHI Grant Number 19K09209.

摘　　要：Gemcitabine has been used as a key drug for the treatment of pancreatic ductal adenocarcinoma.Although surgery remains the mainstay for cure of this lethal disease,the effect is quite limited,even for resectable disease,if there is no collaboration with chemotherapy.In the cases with unresectable disease,conversion surgery after a favorable response to chemotherapy might show encouraging results.Potentiation of chemotherapeutic agent is urgently needed in almost all stages of pancreatic cancer.Further efforts must be paid on overcoming chemo-resistance by understanding tumor diversity and developing biomarkers that follow recent success of modified conventional agents by drug delivery technology.

关 键 词：GEMCITABINE chemo-resistance pancreatic cancer multi-modal therapy SURGERY 

分 类 号：R73[医药卫生—肿瘤]